

[Review Group]

## Cochrane Upper Gastrointestinal and Pancreatic Diseases Group

Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E, Bennett C, Lilleyman J, Dearness K

Contact details:

Ms Jan Lilleyman  
Leeds

LS2 9LN

UK

enquiries@cochrane.leeds.ac.uk

phone: +44 113 343 5419

fax:

[cochrane.leeds.ac.uk](http://cochrane.leeds.ac.uk)

*About The Cochrane Collaboration* Published in Issue 1, 2009

Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

This version first published online: 15 April 2009 in Issue 2, 2009

This record was last updated on: 12 November 2008

---

### What's new

The majority of the group's reviews and protocols have been republished in this issue (January 2009) to reflect the updating of the software used to author reviews, RevMan. All republished reviews and protocols contain no revisions to the text or findings, only revisions to their style and structure.

There are no new reviews or protocols by the Upper Gastrointestinal and Pancreatic Diseases group published in this issue.

The group has published 39 reviews and 26 protocols.

### Editorial information

#### Editorial team

##### Co-ordinating Editors

David Forman, UK  
Paul Moayyedi, Canada

##### Deputy Co-ordinating Editor

Grigorios Leontiadis, Canada

##### Review Group Co-ordinators

Janet Lilleyman, UK  
Karin Dearness, Canada

##### Trials Search Co-ordinator

Racquel Simpson, Canada

##### Editors

Brendan Delaney, UK (Feedback editor)  
Javier Gisbert, Spain  
Ernst Kuipers, Netherlands  
Richard Malthaner, Canada  
Paul Moayyedi, Canada  
Alaa Rostom, Canada

##### Medical Statistician

Noori Akhtar-Danesh

##### Support to the editorial base

Cathy Bennett, UK

##### Secretary

No appointment

### **Volunteer**

Dr Neel Sharma MBChB, BSc (Hons)  
Foundation Year One Doctor  
Barts and the London NHS Trust  
Whitechapel  
London E1 1BB

### **Contact details:**

Dr Cathy Bennett/Jan Lilleyman/Karin Dearness  
University of Leeds  
30-32 Hyde Terrace  
Leeds  
LS2 9LN  
UK  
[enquiries@cochrane.leeds.ac.uk](mailto:enquiries@cochrane.leeds.ac.uk)

Please note that due to staff changes and organisation of the editorial base, the office at the University of Leeds is no longer staffed on a full time basis. Editorial support is divided between the University of Leeds in the UK and McMaster University in Hamilton. For enquiries, please use the E-mail address above. E-mail is accessed daily. While we will endeavor to reply as soon as possible, our response to your enquiry may take several days.

Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

### **Reviewers**

Authors (also known as Reviewers) and Co-authors of published protocols and reviews. This list includes active reviewers with publications on this issue of the Cochrane Library.

- Shahab Abid, Pakistan
- Ajit T Abraham, UK
- Radamés Isaac Adefna Pérez, Cuba
- Nadeem Afzal, UK
- Marjan Aghazahedi, Canada
- Ali Ajaz, UK
- Hakima Al-Hashimi, Bahrain
- Mamun Al-Mahtab, Bangladesh
- Mohammed Al-Omran, Canada
- Ahmed Al-asfoor, Bahrain
- Suhail Alam, UK
- Victor Alberto, UK
- Derek Alderson, UK
- Dunia Alhashimi, Bahrain
- Carlos Almeida, Brazil
- Régis B Andriolo, Brazil
- Gerd Antes, Germany
- Sydney J Arnott, UK
- Álvaro N Atallah, Brazil
- Cristina Augood, UK
- Vicente B Avanzado, Philippines
- Khurram Ayub, UK
- Zheng Gang Bai, China
- Dipika Bansal, India
- Alan Barkun, Canada
- Hugh Barr, UK
- Sreeshyla Basavaraj, UK
- Claudio Bassi, Italy
- Rommel Bataclan, Philippines
- Franco Bazzoli, Italy
- R. Mark Beattie, UK
- Susanne Behl, Germany
- Cathy Bennett, UK
- Amanda Bevan, UK
- Pradeep Bhandari, UK
- Deepak Bhasin, India
- Li Bo, China
- Girish Boggaram, UK
- Peter Bonis, USA

- Michel Boucher, Canada
- Cedric G Bremner, USA
- Luciano Bressy, Brazil
- Nathalie Broutet, Switzerland
- Duff M Bruce, UK
- Julie Bruce, UK
- Enric Brullet, Spain
- Susan Brunskill, UK
- Markus W Büchler, Germany
- John S de Caestecker, UK
- Bin Cai, China
- Xavier Calvet, Spain
- Marion K Campbell, UK
- Rafael Campo, Spain
- Fernando Carballo, Spain
- Juan Castellanos González, Cuba
- Saeed Chaudhary, UK
- Fang Xue Chen, China
- Guangyuan Chen, China
- Guwei Chen, China
- Jia-Ping Chen, China
- Xiaoyan Chen, China
- Xin-Zu Chen, China
- Zhi-Xin Chen, China
- Zhiyu Chen, China
- Naoki Chiba, Canada
- Waldeciro Colaco, Brazil
- Sarah Collin, UK
- Cristiane Conti, Brazil
- Simone Coulaud-Cunha, Brazil
- William Raine Craig, Canada
- Adrian Crellin, UK
- Lourdes Daez, Philippines
- Ma Lourdes O Daez, Philippines
- Brian R Davidson, UK
- John DeCaestecker, UK
- Tom R DeMeester, USA
- Jonathan J Deeks, UK
- Brendan Delaney, UK
- John Dent
- Markus Diener, Germany
- Enrique Dominguez-Muñoz, Spain
- Clare Donnellan, UK
- Carolyn Doree, UK
- Carolyn J Doree, UK
- Stephanie Dorward, UK
- Catherine Dube, Canada
- W Duncan, UK
- Shyam Kiran Duvvi, UK
- Frederic Eckhauser, USA
- Regina El Dib, Canada
- Elizabeth J Elliott, Australia
- Layli Eslami, Iran
- Simon M Everett, UK
- Carlo Fallone, Canada
- Saul N Faust, UK
- Zbys Fedorowicz, Bahrain
- Deborah Fenlon, Canada
- Gilmar Fernandes do Prado, Brazil
- Meg Finch-Jones, UK
- Lori Fischbach, USA
- Isobel Fitzgerald-O'Connor
- Rebecca C Fitzgerald, UK
- Wolfgang E. Fleig, Germany
- Alex C Ford, Canada
- David Forman, UK

- YouJuan Fu, China
- Ate v.d. Gaast, Netherlands
- Joaquin Gama-Rodrigues, Brazil
- Tao Gan, China
- Elizabeth Gardener, UK
- Emili Gené, Spain
- Aneesh T George, India
- Anahita Ghorbani, Iran
- M Gignoux, France
- Ruth E Gilbert, UK
- David Girling, UK
- Javier P Gisbert, Spain
- Lise Lotte Gluud, Denmark
- Jason Goh, UK
- David Goldstein, Australia
- Claudio A. R. Gomes Jr, Brazil
- Jose Gomez-Leon, Venezuela
- Adrian Grant, UK
- Susi R Green, UK
- Ala Groof, Saudi Arabia
- Winfried WG Grothe, Germany
- Axel AG Grothey, USA
- Quanlin Guan, China
- Zhen Guo, China
- Kurinchi Selvan Gurusamy, UK
- Johannes Haerting, Germany
- Ana Hanlon-Dearman, Canada
- H Hansen, UK
- Aenone Harper, UK
- Peter Harper, UK
- Adam Harris, UK
- Keith Harris, UK
- Chittinad Havanond, Thailand
- Piyalamporn Havanond, Thailand
- JiDong He, China
- Xiaodong He, China
- Sarah Hearnshaw, UK
- Brook Hefright, USA
- Per Hellstrom, Sweden
- Christina Heukaeufer, Germany
- Steven D Heys
- Alex Hicks, UK
- Bernie Higgins, UK
- Richard Hobbs, UK
- Ralf Hofheinz, Germany
- Marjolein Y.V. Homs, Netherlands
- Karen Hovhannisyan, Denmark
- Colin W Howden, USA
- Jian-Kun Hu, China
- Yang Hu, China
- J Q Huang, Canada
- Yuchuan Huang, China
- Yinghua Hui, China
- Richard Hunt, Canada
- Brian Hutton, Canada
- Chris Hyde, UK
- Regina Imada, Brazil
- Michael Innes, UK
- Naureen Iqbal, UK
- Francoise Themis Izquierdo Lara, Cuba
- Wasim Jafri, Pakistan
- Janusz Jankowski, UK
- Jiafu Ji, China
- Ji Jiafu, China
- Hua Jiang, China
- Kun Jiang, China

- Lei Jiang, China
- Zhuming Jiang, China
- Shuli J Jin, China
- Tang Jinling, Hong Kong
- Emilie Jolicoeur, Canada
- Janet L. Joyce, Canada
- Shadi Kalantarian, Iran
- Soumik Kalita, India
- Guneeth Kalra, UK
- Yan Kang, China
- Chris Karapetis, Australia
- Christos Karapetis, Australia
- Fazal Karim, Bangladesh
- Geert Kazemier, Netherlands
- Hussain Kazi, UK
- Mostafiz Khan, Canada
- Shahab Khatibzadeh, Iran
- Sam Khorrami, Spain
- Ganessan Kichenadasse, Australia
- Peter Kienle, Germany
- Naveed Kirmani, UK
- Gerhard GK Kleber, Germany
- Sarah Louise Klingenberg, Denmark
- Hanns-Peter Knaebel, Germany
- Hemant Kocher, UK
- Zygmunt Krukowski, UK
- Ernst J. Kuipers, Netherlands
- Renata H Kukuruzovic, Australia
- Raj Kumar, India
- Eternity Labio, Philippines
- Raymond Lahaie, Canada
- Robert Laheij, Netherlands
- Ebbe Langholz, Denmark
- Pierre Lao-Sirieix, UK
- Mike Larvin, UK
- Joseph Lau, USA
- Bernard Launois, France
- Armando Leal Mursulí, Cuba
- Grigoris I Leontiadis, Canada
- Maxine Lewis, Canada
- Jan E Leyden, Ireland
- Bo Li, China
- Chun-Mei Li, China
- Jun Li, China
- Wen Huan Li, China
- Yaodong Li, China
- You Zhang Li, China
- Youping Li, China
- Yumin Li, China
- Greger Lindberg, Sweden
- Fucheng Liu, China
- Geng Liu, China
- Guan Jian Liu, China
- Ruifeng Liu, China
- Ya Li Liu, China
- Stuart Logan, UK
- Benjamin Loveday, New Zealand
- Chuanxin Luo, China
- HongTao Luo, China
- Suzana AS Lustosa, Brazil
- Tinghong Lv, China
- Bin Ma, China
- Suzanna MacLennan, Australia
- Padraic MacMathuna, Ireland
- Reza Malekzadeh, Iran
- Samir Malhotra, India

- Efstratios Maltezos, Greece
- Richard Malthaner, Canada
- Joseph Mamazza, Canada
- Jonathan E Markowitz, USA
- Sigrid Monina I Marquez, Philippines
- Delcio Matos, Brazil
- Sharon McCann, UK
- Peter McCulloch, UK
- Jessie McGawan, Canada
- Jessie L McGowan, Canada
- Linda McIntyre, UK
- Sharon McLeer, UK
- Francis Megraud, France
- M Sohail Mirza, UK
- George (JJ) Misiewicz, UK
- Anubhav Mittal, New Zealand
- Paul Moayyedi, Canada
- Michael Moffatt, Canada
- Husein Mooloo, Canada
- Carolina Monteiro, Brazil
- Carlos Hernando Morales Uribe, Colombia
- Eva Morris, UK
- Alan C Moss, USA
- Ashley Mowat, UK
- Katherine Muir, Canada
- Mubashir Mulla, UK
- Michael F Murphy, UK
- Romeu Kiyotaka Nakamura, Brazil
- Siavosh Nasser-Moghaddam, Iran
- Liu Ning, China
- Marcelo Eidi Nita, Brazil
- Louise Nott, Australia
- Mattijs ME Numans, Netherlands
- K Nygaard, Norway
- Edward (Ted) V O'Loughlin, Australia
- Siobhan O'Neill, Australia
- R Oakes, UK
- Giuseppina Oderda, Italy
- Oesophageal Cancer Collaborative Group, UK
- Marcio M Oliveira, Brazil
- Ralph Santos Oliveira, Brazil
- Domenico Palli, Italy
- Tao Pan, China
- Promila Pandhi, India
- Kenneth GM Park
- Mahesh K B Parmar, UK
- Wendy Parulekar, Canada
- Richard Pena, Venezuela
- K Penumetcha
- John Victor Peter, India
- Anthony Phillips, New Zealand
- Bart van Pinxteren, Netherlands
- Eric C Poulin, Canada
- Cathy Preston, UK
- Timothy Price, Australia
- Youlin Qiao, China
- Xia Qing, China
- Michelle Qume, UK
- Krish Rangunath, UK
- Nuh Rahbari, Germany
- Salimur Rahman, Bangladesh
- Rodrigo Ramos, Brazil
- Surinder Rana, India
- Jonathan Rees, UK
- Sarah Rhodes, UK
- Z Rhugang, China

- A Roalfe, UK
- Ulrich Ronellenfitsch, Germany
- Alaa Rostom, Canada
- A Rousell, France
- Elham Sabri, Canada
- Humberto Saconato, Brazil
- Pulak Sahay, UK
- Alvaro Sanabria, Colombia
- Jose Santana, Canada
- Vincenzo Savarino, Italy
- Matthias Schwarzbach, Germany
- Guido Schwarzer, Germany
- Surjit S Sehmbly, India
- Christoph M Seiler, Germany
- Nusrat Shafiq, India
- Ying Shao, China
- Nav Sharma, UK
- Neel Sharma, UK
- Virender Kumar Sharma, USA
- Henry Sharp, UK
- Soo Shelly, UK
- Xiao Xiao Shi, China
- Shabir Siddhu, India
- Peter D. Siersema, Netherlands
- Suzana Angelica Silva Lustosa, Brazil
- Cristiane da Silva, Brazil
- Chris Sinclair, Canada
- Raj Singh, Malaysia
- John Slavin, UK
- Shelly Soo, UK
- G Spiliopoulos, France
- Aravamuthan Sreedharan, UK
- Vivek Srivastava, UK
- Wilko Staiger, Germany
- Christopher B Steer, Australia
- Lesley Stewart, UK
- Ewout W. Steyerberg, Netherlands
- Andrew Strickland, Australia
- Shao Liang Sun, China
- Shayne P Taback, Canada
- Shayne P Taback, Canada
- Nicholas J Talley, USA
- Wen-Fu Tang, China
- Xudong Tang, China
- Ashref Tawil, UK
- Prathap Tharyan, India
- Jo Thompson
- Jin Hui Tian, China
- Ling Tian, China
- Xiaojuan Tian, China
- Jayne Tierney, UK
- Mark Tighe, UK
- Simon Travis, UK
- Peter Tugwell, Canada
- Peter Unge, Sweden
- Satyanarayana S Vedula, USA
- Mercedes Vergara, Spain
- David Vernon, New Zealand
- Eduardo Villatoro, UK
- Maria Isabel Villegas, Colombia
- Annemarie de Vries, Netherlands
- Anna Dorothea ADW Wagner, Germany
- Yiping Wang, China
- Hao Wang, China
- Hongyuan Wang, China
- Jie Zhen Wang, China

- Jun Wang, China
- Lei Wang, China
- Li Wang, China
- Li Wang, China
- M Wang, UK
- Ping Wang, China
- Qiong Wang, China
- Weiwu Wang, China
- XiaoHu Wang, China
- Tao Wei, China
- Wenqiang Wei, China
- Xin Wei, China
- Vivian Welch, Canada
- George A Wells, Canada
- Amy AW Wen, China
- Moritz N Wentz, Germany
- Samantha M Wileman, UK
- Derek Wilke, Canada
- Sue Wilson, UK
- John Windsor, New Zealand
- Angela Wong, UK
- Rebecca KS Wong, Canada
- Sally Wortley, Australia
- Evan Wu, China
- Taixiang Wu, China
- Zongying Wu, China
- Qing Xia, China
- Tianpeng Xie, China
- Guangwei Xu, China
- Hong Xu, China
- Kui Xu, China
- Xincheng Xue, China
- Javed Yakoob, Pakistan
- Chunxia Yang, China
- Jin Yang, China
- Jinlin Yang, China
- Juan Yang, China
- Ke Hu Yang, China
- Kun Yang, China
- Lijuan Yang, China
- Shujuan Yang, China
- Sun Hu Yang
- Sunhu Yang, China
- Xiaonan Yang, China
- Xiaoyan Yang, China
- Xunzhe Yang, China
- Hong Yin, China
- Zhang Yin, China
- Lin Ying, China
- Mingying Ying, China
- Desmond Yip, Australia
- Fu YouJuan, China
- Ji Ren Yu, China
- Wenzhen Yuan, China
- Yong Yuan, China
- Muhammad Shabbir Yusuf, Pakistan
- Chao Zeng, China
- Xiaoxi Zeng, China
- Hong Zhai, China
- Bo Zhang, China
- Chunqing Zhang, China
- Li Zhang, China
- Rui Zhang, China
- Youcheng Zhang, China
- Pengcheng Zhao, China
- Yongfan Zhao, China



- Jianwei Zheng, China
- Tang ZhiMei, China
- Zong-Guang Zhou, China
- Hua Bin Zou, China
- Xia Zuqing, China

**Additional contributors**

Peer referees of published protocols and reviews

We would like to thank those named below for acting as peer referees to the reviews and protocols published in the UGPD Group's module in *The Cochrane Library*. We are extremely grateful for your time, knowledge and help.

Ad Masclee  
Alan Barkun  
Andre Smout  
Andrew Goddard  
Angel Lanas  
Anne Duggan  
Annemiek Cats  
Brendan Drumm  
B Gold  
BK Sandhu  
Billy Bourke  
Brendan Delaney  
C Karalambos Gogos  
Carlo Fallone  
Carmelo Lafuente  
Casper van Eyck  
Chandu Bardhan  
Chris Dervenis  
Chris Hawkey  
Chris Williams  
Christian Gouillat  
Christoph Seiler  
Cliodna McNulty  
Colm O'Morain  
Darell Heiselman  
David Armstrong  
David Cunningham  
David Kirby  
Declan Carey  
Derek Alderson  
Domenico Palli  
Dr Charnley  
Duncan Colin-Jones  
Edzard Ernst  
Eliza Wong  
Enrique Dominguez-Munoz  
Enrique Quintero  
Erik De Koster  
Erik Rauws  
Ernst Kuipers  
Fabio Luison  
Fast Feu  
Fernando Carballo  
Grigorios Leontiadis  
Gretchen Purcell  
Glyn Jamieson  
Greg Rubin  
HG Beger  
Henk Festen  
Hugo Hazenberg  
Iain Martin  
J Dalby-Payne  
Jon Markowitz  
J Misiewicz  
J. Enrique Dominguez-Munoz

J. N. Primrose  
Jack Miller  
James Gildersleve  
Jan Dees  
Jan Hatleback  
Jan Tack  
Janusz Janowski  
Javier Gisbert  
Jayne Tierney  
Jeffrey Jackson  
Joe Sung  
Joel Richter  
John Baxter  
John De Caestecker  
John Fielding  
John Lee  
John Neoptolemus  
John Puntis  
John Toouli  
Jon Deeks  
Jorg Melzer  
Joseph Sung  
Justin Waters  
Kelvin Pamler  
Ken McColl  
Kevin Dolan  
Klaus Linde  
Kyodi Adachi  
Liisa Jaakkimainen  
Liz Gardener  
Lori Fischbach  
M S Khuroo  
M. Sinaasappel  
M. W. Buchler  
Marc Rothenberg  
Marco Bruno  
Masaharu Tatsuta  
Mattijs Numans  
Miguel Pérez-Mateo  
Mike Griffin  
Mike Larvin  
Bob Mason  
Naoki Chiba  
Nanno H. Mulder  
Niek de Wit  
Nicholas Talley  
Phil Katz  
Paul Moayyedi  
Padi Hungin  
Peter Harper  
Peer Wille-Joergensen  
Peter Matzen  
Peter Kahrilas  
Phillipa Middleton  
Peter Siersema  
Rainer Isenmann  
R. Finley  
Richard Malthaner  
Reinhard Saller  
Rene Lambert  
Robert Laheij  
Robert Heading  
SR Orenstein  
Ruth Gilbert  
Sander Van Zanten  
Seamus O'Mahony

Sheila Greenfield  
Shelly Soo  
Simon Wessely  
Thierry Conroy  
Tom Jefferson  
Vincente Garriges  
Vincenzo Savarino  
Walter Pearson  
William Steward  
Xavier Calvet

#### **Handsearchers**

Prof Enno Hentschel  
Dr John Midgeley

#### **Supporting Cochrane Centre**

UK

#### **Acknowledgements**

The UGPD group acknowledge the invaluable contribution of Jo Webb (former Trials Search Co-ordinator), Elizabeth Gardener (former Statistical Editor), Iris Gordon (former Trials Search Co-ordinator) and Gemma Sutherland (former Administrative Assistant).

We also thank Robin Waxman for her proof reading assistance, and for her unique database design skills!

Contributors to the Specialised Register:

Adam Harris, UK - donation of database of trials  
Richard Hunt (Dr J Huang), Canada - donation of databases of trials  
Jean Paul Galmiche, France - donation of extensive reference list

We gratefully acknowledge the support of the Cochrane Cancer Network in the location of trials, peer referees and general support.

The Meta Analysis Group of the MRC Trials Office, Cambridge UK converted an individual patient data review of pre-operative radiotherapy in operable cancer of the oesophagus (on behalf of the Oesophageal Cancer Collaborative Group).

#### **Sources of support**

##### ***External sources of support***

- AstraZeneca (Systematic Reviews Workshop on H. pylori eradication, June 1999), UK
- NHS Research and Development Programme (Core Support), UK
- Glaxo Wellcome (Exploratory Meeting, October 1996), UK
- NHS HTA Programme (Systematic Reviews of Management of Non-Ulcer Dyspepsia), UK
- Oxfordshire Health Authority Charitable Fund (Systematic Review), UK
- Astra (Exploratory Meeting, October 1996), UK

##### ***Internal sources of support***

- University of Leeds, UK

#### **Consumer involvement**

Consumer representative: Mr David Kirby (Oesophageal Patients Association, UK)

Any relevant involvement by consumers (people with the relevant health care condition, their carers, policy makers, health professional, and others who may make use of the reviews prepared by the CRG) is welcomed by the UGPD Group. At present, consumers act as peer referees for protocols and reviews which have been prepared by the UGPD Group. However, we intend to expand the role of consumers, possibly to include production of patient support and information leaflets, and welcome enquiries from interested parties.

#### **Involvement of other users**

#### **Conflict of interest**

No conflicts of interest are known

#### **Background**

Discussions concerning the formation of an Upper Gastrointestinal (GI) Cochrane Review Group (CRG) began in 1993, when a number of meetings were held to develop the work of the Cochrane Collaboration in GI disease in general. These led to the

formation of the Inflammatory Bowel Disease (IBD) CRG and the Hepatobiliary CRG. It was clear that there was also a need for a CRG in upper GI disease, not least because of the enormous health service costs involved in the clinical management of dyspepsia, and the burgeoning number of clinical trials of variable quality.

Professor David Forman, now Co-ordinating Editor of the UGPD Group, has a long established research interest in the clinical impact of *Helicobacter pylori* infection. This seemed to be a subject that demanded methodologically robust review if it was to lead to meaningful and practical conclusions for doctors and their patients.

A "Dyspepsia CRG" exploratory meeting took place on 16th October 1996 in Copenhagen. All those who had contacted the Cochrane Collaboration with an interest in this area of medicine were invited. Also present were people known to have an interest in reviews of dyspepsia, representatives of the IBD and Hepatobiliary CRGs, the Cochrane Cancer Network, and the two pharmaceutical companies (Glaxo-Wellcome and Astra Hassle), who had agreed to support the event. The meeting was chaired by Andy Oxman on behalf of the Collaboration.

There was unanimous and enthusiastic support in favour of establishing a CRG, although it was felt that the scope of the Group should also include all diseases of the oesophagus, stomach and duodenum (including malignancies). To reflect this widened scope, a provisional title of "Oesophageal, Gastric and Duodenal Diseases CRG" was adopted. It was agreed that The University of Leeds should be the editorial base and that Professor Forman should be the prospective Co-ordinating Editor.

The name changed again in February 1998 to Upper Gastrointestinal and Pancreatic Diseases Group (UGPD), to reflect the integration of pancreatic diseases into the scope of the Group.

Formal registration of the UGPD Group took place on 1 June 1998.

Funding to support the core activities is now in place until March 2010. The Group maintains its Editorial Base at the University of Leeds, UK, and has a Satellite Centre at McMaster University in Canada, with Professor Paul Moayyedi as Joint Co-ordinating Editor.

### **Cochrane UGPD Group Editors' Meetings**

1. 16th November 1999, at the Osservatorio Epidemiologico Regionale, Rome.
2. 27th November 2000, UEGW Meeting, in Brussels, Belgium.
3. 21st May 2001, DDW Meeting, Atlanta, US.
4. 20th May 2002, DDW Meeting, San Francisco, US.
5. 20th May 2003, DDW Meeting, Orlando, US.
6. 16th May 2005, DDW Meeting, Chicago, US.

### **Scope**

"To use evidence from randomised controlled trials to answer practical questions of the prevention, treatment and rehabilitation of benign and malignant disorders of the oesophagus, stomach, duodenum and pancreas. Systematic reviews of other types of trials will be used where necessary."

There are possible areas of mutual interest with other Cochrane Gastrointestinal Groups, i.e. [Hepato-Biliary Group](#), [Inflammatory Bowel disease and Functional Bowel Disorders Review Group](#) and [Colorectal Cancer Review Group](#). Other Cochrane Review Groups (CRGs) which share a potential common interest include those which address interventions which may have an effect on the upper gastrointestinal system (for example, NSAIDs in musculoskeletal problems). Every attempt will be made to ensure that duplication of work does not occur and that support is given to other CRGs who wish to take responsibility for review topics where there is mutual interest. In particular, we would aim to support CRGs by suggesting peer referees and by searching our specialised register for appropriate trials. All interventions (surgical, pharmacological, educational, psychological etc.) for prevention, treatment (acute and maintenance) and rehabilitation will be covered.

The CRG's policy on outcome variables is under development. Many reviews will include death, recurrence of illness, improvement of symptoms, or eradication of *Helicobacter pylori* as an outcome.

### **Glossary**

### **Specialised register**

#### **Inclusion criteria**

The specialised register for the group will include reports of trials in any language, in the prevention, treatment and rehabilitation of benign and malignant diseases of the upper gastrointestinal tract including disorders of the oesophagus, stomach, duodenum and pancreas.

Gastrointestinal adverse effects of certain treatments, for example NSAIDs, are also included in the register of clinical trials. Oesophageal and gastric varices are included by the Hepato-Biliary group, pancreatic complications of cystic fibrosis are covered by the Cystic Fibrosis Group and these are therefore not included in the UGPD register. A full list of the subjects that are covered by the group's specialised register is given in the Topics list.

**Search strategies for the identification of studies****Electronic searches**

The UGPD Group searches The Cochrane Controlled Trials Register to identify controlled clinical trials for inclusion in the specialised register. Handsearching of specialist journals and conference proceedings are being carried out to uncover further studies. Relevant unpublished studies will be included where available.

The UGPD Group Search Strategy for The Cochrane Controlled Trials Register has been derived from MeSH subject headings of digestive system diseases and surgical procedures, which are relevant to the scope of the Group. Appropriate free text terms have been used in conjunction with the MeSH headings to identify reports of randomised and controlled clinical trials. This strategy is under development and further search terms will be added to ensure that all trials relevant to the scope of the UGPD Group are retrieved.

In particular, further work is required to ensure that treatments and all surgical interventions for the upper gastrointestinal tract and the pancreas are adequately covered by the search terms.

The Cochrane Controlled Trials Register is searched quarterly, after each new issue of the Cochrane Library, using the following strategy. Staff at the satellite centre of the group are currently updating the search strategy and register and expect to publish revised details in the next module (April 2009)

1. ESOPHAGEAL-MOTILITY-DISORDERS\*:ME
2. GERD OR GORD
3. (GASTRO-OESOPHAGEAL OR GASTRO-ESOPHAGEAL OR GASTROESOPHAGEAL) NEAR REFLUX
4. ESOPHAGITIS\*:ME
5. (OESOPHAGITIS or ESOPHAGITIS)
6. #1 OR #2 OR #3 OR #4 OR #5
7. ESOPHAGEAL-NEOPLASMS:ME
8. OESOPHAG\* OR ESOPHAG\*
9. NEOPLASM\* OR CANCER\* OR CARCIN\* OR MALIGNAN\* OR TUMOUR\* OR LYMPHOMA
10. #7 OR (#8 AND #9)
11. (STRICTURE OR NARROW\*)
12. #11 AND #8
13. ACHALASIA
14. SPHINCTER NEXT PRESSURE
15. #13 OR (#14 AND #8)
16. DYSMOTILITY OR MOTILITY
17. #16 AND #8
18. ESOPHAGEAL-DIVERTICULUM:ME
19. DIVERTIC\*
20. #18 OR (#19 AND #8)
21. RING\* AND WEB\*
22. (FUNGAL OR VIRAL OR BACTERIAL OR PARASITIC) AND (INFECTION OR INFECTIONS)
23. (#21 OR #22) AND #8
24. #6 OR #10 OR #12 OR #15 OR #17 OR #20 OR #23
25. ESOPHAGEAL-PERFORATION\*:ME
26. PERFORAT\* OR RUPTURE\*
27. MALLORY NEXT WEISS
28. #27 OR #25 OR (#8 AND #26)
29. HEMATOMA:ME
30. HAEMATOMA OR HEMATOMA
31. (#29 OR #30) AND #8
32. ESOPHAGEAL-ATRESIA:ME
33. HERNIA-HIATAL:ME
34. HERNIA AND HIAT\*
35. #32 OR #33 OR #34
36. ESOPHAGEAL-STENOSIS:ME
37. ESOPHAGEAL-FISTULA:ME
38. #36 OR #37
39. FISTUL\*
40. OBSTRUCTION
41. FOREIGN-BODIES\*:ME
42. #8 AND (#39 OR #40 OR #41)
43. #28 OR #31 OR #35 OR #38 OR #42
44. #24 OR #43
45. HELICOBACTER-PYLORI:ME
46. PYLORI
47. #45 OR #46
48. PEPTIC-ULCER\*:ME

49. STOMACH OR GASTR\* OR PEPTIC OR DUODEN\*
50. ULCER\*
51. ZOLLINGER-ELLISON
52. #48 OR #51 OR (#49 AND #50)
53. STOMACH-NEOPLASMS:ME
54. #53 OR (#9 AND #49)
55. STOMACH-DISEASES\*:ME
56. GASTRITIS OR MENETRIER\*
57. INTESTINAL AND METAPLASIA
58. #55 OR #56 OR #57
59. ATROPHY OR POLYP\*
60. HAMARTOMAS OR ISCHEMIA OR LIPOMA OR LIPOSARCOMA
61. #49 AND (#59 OR #60 OR #22)
62. POSTGASTRECTOMY-SYNDROMES\*:ME
63. DUMPING NEAR SYNDROME
64. #58 OR #61 OR #62 OR #63
65. CELIAC-DISEASE:ME
66. WHIPPES-DISEASE:ME
67. SPRUE-TROPICAL:ME
68. LACTOSE-INTOLERANCE:ME
69. CELIAC OR WHIPPLE\* OR (TROPICAL AND SPRUE) OR (LACTOSE AND INTOLER\*)
70. #65 OR #66 OR #67 OR #68 OR #69
71. GASTROINTESTINAL-HEMORRHAGE\*:ME
72. HEMORRHAGE OR HAEMORRHAGE OR BLEED\* OR REBLEED\*
73. PERFORAT\* OR RUPTURE\*
74. #71 OR ((#72 OR #73) AND #49)
75. DUODENAL-DISEASES:ME
76. AFFERENT-LOOP-SYNDROME:ME
77. #75 OR #76
78. DYSPEPSIA:ME
79. GASTROPARESIS
80. REFLUX OR EROSION
81. #80 AND #49
82. #78 OR #79 OR #81
83. #44 OR #47 OR #52 OR #54 OR #64 OR #70 OR #74 OR #77 OR #82
84. ENDOSCOPY-DIGESTIVE-SYSTEM:ME
85. DUODENOSCOPY:ME
86. GASTROSCOPY:ME
87. ESOPHAGOSCOPY:ME
88. CHOLANGIOPANCREATOGRAPHY-ENDOSCOPIC-RETROGRADE:ME
89. ERCP OR (ENDOSCOPIC AND RETROGRADE AND CHOLANGIOPANCREATOGRAPHY)
90. ENDOSCOPI\* OR DUODENOSCOPI\* OR GASTROSCOP\*
91. #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90
92. FUNDOPLICATION:ME
93. FUNDOPLICATION
94. #92 OR #93
95. DILATATION:ME
96. BALLOON-DILATATION\*:ME
97. (((EDER-PEUSTOW or CELESTIN) or BALLOON) AND DILATATION)
98. #8 AND (#95 OR #96 OR #97)
99. DUODENOSTOMY:ME
100. ESOPHAGECTOMY:ME
101. ESOPHAGOPLASTY:ME
102. ESOPHAGOSTOMY:ME
103. ESOPHAGOGASTRECTOMY OR OESOPHOGASTRECTOMY
104. GASTRECTOMY:ME
105. ENDOSCOPIC AND MUCOSAL AND RESECTION
106. #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105
107. BILROTH OR ROUX-EN-Y
108. ANASTOMOSIS-ROUX-EN-Y:ME
109. VAGOTOMY\*:ME
110. VAGOTOMY AND (GASTROENTEROSTOMY OR PYLOROPLASTY)
111. GASTROENTEROSTOMY\*:ME
112. #107 OR #108 OR #109 OR #110 OR #111
113. GASTROPLASTY:ME
114. GASTROSTOMY:ME

115. JEJUNOSTOMY:ME
116. GASTROJEJUNOSTOMY OR JEJUNOSTOMY
117. #113 OR #114 OR #115 OR #116
118. #106 OR #112 OR #117
119. #83 OR #91 OR #98 OR #118
120. ANTI-ULCER-AGENTS:ME
121. ANTIULCER NEXT AGENT\*
122. ANTI-ULCER NEXT AGENT\*
123. #120 OR #121 OR #122
124. HISTAMINE-H2-ANTAGONISTS:ME
125. HISTAMINE NEAR ANTAGONIST\*
126. RECEPTOR\* NEAR ANTAGONIST\*
127. CIMETIDINE:ME
128. FAMOTIDINE:ME
129. NIZATIDINE:ME
130. RANITIDINE:ME
131. CIMETIDINE OR FAMOTIDINE OR NIZATIDINE OR RANITIDINE
132. #124 OR #125 OR #126 OR #127 OR #128 OR #129 OR #130 OR #131
133. OMEPRAZOLE:ME
134. (PROTON NEXT PUMP) NEAR INHIBITOR\*
135. (PROTON NEXT PUMP) NEAR BLOCKER\*
136. OMEPRAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR RABEPRAZOLE
137. #133 OR #134 OR #135 OR #136
138. PROKINETIC NEAR AGENT\*
139. ERYTHROMYCIN OR DOMPERIDONE OR METOCLOPRAMIDE OR CISAPRIDE
140. ERYTHROMYCIN:ME
141. DOMPERIDONE:ME
142. METOCLOPRAMIDE:ME
143. #138 OR #139 OR #140 OR #141 OR #142
144. ALGINATES:ME
145. ALUMINUM-HYDROXIDE:ME
146. ALGICON OR ALGINATE\*
147. CALCIUM-CARBONATE:ME
148. MAGNESIUM-HYDROXIDE:ME
149. MAGNESIUM-OXIDE:ME
150. SODIUM-BICARBONATE:ME
151. #144 OR #145 OR #146 OR #147 OR #148 OR #149 OR #150
152. ALTACITE\* OR ASILONE\*
153. GASTROCOTE\* OR GAVISCON\*
154. HYDROTALCITE\* OR MAALOX\*
155. MUCAINE
156. #152 OR #153 OR #154 OR #155
157. ALUMIN\* NEXT HYDROXIDE\*
158. CALCIUM NEXT CARBONATE\*
159. MAGNESIUM NEXT HYDROXIDE\*
160. MAGNESIUM NEXT OXIDE\*
161. MAGNESIUM NEXT TRISILICATE\*
162. SODIUM NEAR BICARBONATE\*
163. SODIUM NEAR CARBONATE\*
164. #157 OR #158 OR #159 OR #159 OR #160 OR #161 OR #162 OR #163
165. CARBENOXOLONE:ME
166. MISOPROSTOL:ME
167. SUCRALFATE:ME
168. MUCOSAL AND PROTECTING AND AGENT\*
169. CARBENOXOLONE OR MISOPROSTOL OR SUCRALFATE
170. #165 OR #166 OR #167 OR #168 OR #169
171. MUSCARINIC-ANTAGONISTS:ME
172. DICYCLOMINE:ME
173. PIRENZEPINE:ME
174. PROPANTHELINE:ME
175. ANTIMUSCARINIC\*
176. MUSCARINIC NEAR ANTAGONIST\*
177. DICYCLOMINE OR METHANTHELINE OR PIRENZEPINE
178. PROPANTHELINE
179. #171 OR #172 OR #173 OR #174 OR #175 OR #176 OR #177 OR #178
180. #123 OR #132 OR #137 OR #143 OR #151 OR #156 OR #164 OR #170 OR #179 181 #119 or (#180 and (#49 or #8))

### **Hand searching**

The UGPD has registered with the New England Cochrane Centre their intention to handsearch the following specialist journals:

#### **Journals:**

- Acta Medica Austriaca 1990-
- Alimentary Pharmacology and Therapeutics, 1987-
- Canadian Journal of Gastroenterology. 1987-
- Cancer Research, 1980-
- Digestive Endoscopy. 1989-
- European Journal of Gastroenterology & Hepatology. (1989-1994)
- Helicobacter. 1996-
- International Journal of Pancreatology. 1986-
- Pancreas. 1986-

#### **Conference Proceeding:**

Digestive Disease Week. 1997 May 11-14; Washington DC.

Journals being handsearched by the Biomed project for the UGPD Group

The Biomed handsearching project is a three year project in which seven European Cochrane Centres collaborate to handsearch western European specialized health care journals. The Biomed project has undertaken to handsearch the following journals on behalf of the UGPD group:

- Acta Endoscopica
- Acta Gastro-enterologica Belgica
- Annales de Gastroenterologie et d'Hepatology
- Chirurgia Gastroenterologica
- Chirurgische Gastroenterologie Endoskopie Heute
- Gastrum Patologia del Aparato Digestva. Gastro-Enterologie Clinique et Biologie
- Gastro-Enterologia y Hepatologia
- Gastroenterologisches Journal
- Italian Journal of Gastroenterology and Hepatology
- Revisiones en Gastroenterologia. Revista Andaluza de Patologia Digestiva
- Revista de la Asociacion Castellana del Aparato Digestivo
- Revista Espanola de Enfermedades Digestivas
- Revue Francaise de Gastro-enterologie
- Sociedad Valenciana de Patologia Digestiva

#### **Other strategies**

For each review a search strategy is produced based on relevant clinical terms agreed by the author and the Trials Search Co-ordinator. The search strategy is constructed using a combination of Mesh terms and free text terms. All reports of randomised controlled trials identified whilst searching will be added to the Group's Specialised Register. Where applicable, the following information sources are searched using an individual search strategy developed for each review:

- The Cochrane Library
- Medline
- Embase
- Cinahl
- Web of Science
- LILACS
- PDQ
- PsychINFO
- AMED
- Current Contents
- SIGLE

The following information sources are searched for all reviews:

- National Research Register
- Medical Research Council (MRC)
- Center Watch
- Clinicaltrials.gov
- Current Controlled Trials
- TrialsCentral

The UGPD Group has been fortunate to receive bibliographies from Adam Harris (UK), Richard Hunt (Canada) and Jean Paul



Galmiche (France), which have been searched and the relevant trials added to our specialised register.

### ***Planned searching activities***

We have identified several non-English language journals and conference proceedings which we feel may contain reports of trials relevant to our Group. These include Japanese Journal of Gastroenterology, Gastroenterological Society of Taiwan Journal, Endoskopie Heute, and many others. However, at present we are unable to identify handsearchers for these, accordingly we have not registered them on the Cochrane Handsearching Masterlist. If you are able to help us with searching non-English language journals, please contact our Trials Search Co-ordinator.

## **Methods used in reviews**

### **Search strategies**

#### ***Access to specialised register by reviewers***

The specialised register is available for all authors to consult through the Cochrane Library. However, to avoid duplication of searching activities and to provide authors with a comprehensive search of the database, the Trials Search Co-ordinator will liaise with authors to construct and develop search strategies for each review, to be carried out at the editorial base. Searches for updating reviews will be carried out at the editorial base by the Trials Search Co-ordinator on an annual basis.

#### ***Additional search strategies***

The Trials Search Co-ordinator will work with the author to create a specific search strategy for each author, which will then be run in EMBASE, CINAHL, and BIDS ISI, in addition to the Cochrane Library. The UGPD Group also liaises with the Cancer Network when searching for authors with cancer related topics. In order to identify unpublished trials, experts in the field and pharmaceutical companies will be contacted for information, and, where applicable, the Internet will also be searched. Reports of trials found by these methods will be added to the UGPD register of trials. Authors should search citations in each trial report for additional trials.

### **Study selection**

The UGPD Group recommends that the trials included are randomised, pseudorandomised or controlled clinical trials which compare the test intervention with placebo or standard treatment. Other types of trials can be used where necessary.

Selection of studies for inclusion in a review should be performed independently by more than one author. The editor assigned to the review will work to resolve differences in study selection between authors.

### **Assessment of methodological quality**

Procedures for the assessment of methodological quality are under development.

Advice on standard criteria for assessing quality will be given by the editorial team. Examples of quality assessment checklists are available. Methods are described in the Cochrane Authors Handbook which is available from the editorial team, on the Cochrane library and via the Cochrane Web sites.

In general:

- An accepted method of quality assessment should be used.
- Quality should be independently assessed by more than one author and the level of agreement should be reported in the review.
- The editor responsible for the development of the review will resolve difference in quality assessment between authors.
- Quality assessment will be reported in the methods and results sections of the review.

### **Data collection**

The UGPD group recommends that the extraction of data is done independently by more than one author. The editor responsible for the development of the review will resolve difference in data interpretation between authors. Data verification with the person responsible for the study will not normally be required other than where the data is unpublished or confirmation of results are required.

Data from RCTs that have not been published will be eligible for use in systematic reviews prepared by the UGPD group, subject to verification of data by the primary investigator. The UGPD Group will not routinely collect and analyse data on rare adverse events collected from non-RCTS.

The UGPD group will request copies of data extraction forms (for included studies) to be submitted to the group when a draft review is submitted for peer referee. Data extraction forms will be retained by the group, for reference or to aid a future review updater, should an initial review author not be able to update a review. Data extraction forms will not be published nor used in any other way by the group or its members.

### **Analysis**

Statistical guidance is available from the editorial base (Statistical Editor: Noori Akhtar-Danesh).

Data entry to RevMan should be done using the double data entry facility which allows more than one author to independently enter data. Policies on statistical methods are under development.

These will incorporate guidance derived from Section 9 of the Authors Handbook on analysing data and undertaking meta-analyses.

Heterogeneity of trials and issues such as crossover trials will be addressed.

### **Reporting of reviews**

Discussion and conclusions section

The strength of the evidence should be categorised using the hierarchy of evidence scale detailed in CRD report 4, available from the editorial base.

The applicability of the results should be commented on taking into account the applicability of the trials to use of the intervention in standard practice for treatment of the disorder. Cost benefit analysis will not be routinely performed.

The use of non-RCT derived data when discussing results and drawing conclusions should be commented on in this section. Where applicable, other reviews will be cross-referenced in this section.

Tables and figures

Information in the excluded and included trials tables should be brief and structured to include the Study Identifier, Methods of the Trial, Participants, Interventions, Outcomes, and further Notes.

Each included study should ideally include a 'Risk of bias' table including information on each study's and/or individual outcomes for bias from: sequence generation; allocation concealment; blinding; incomplete data, selective reporting or other means.

Studies in the excluded trials table should consist of those trials which were initially selected for assessment, but which later proved to be non-RCTs or ineligible for other reasons. Advice is available from the editorial team on the validity of trials for inclusion into the review.

Table of comparisons

Policies for the structure or order of outcomes are under development and depend to some extent on the outcomes we select as 'default' for this group.

The order of trials in the tables will be alphabetical, then by date. Trials will be named preferably by author surname (e.g. Smith 1998) or, where this is not possible, by trial group identifiers (e.g. Oesophageal Cancer Trials Collaborators Group OCTCG 1997).

There may be multiple publications from one trial. Such reports should be cross referenced to the original study, for example, a publication by Jones et al reporting data from the Oesophageal Trials Collaborators Group study of 1997, should be reported as Jones 1999 (OCTCG 1997).

Any factors which could be perceived as conflict of interest should be stated.

## **Editorial process**

### **Titles**

Review authors are invited to submit titles at any time. In order to reduce the risk of wasted effort, a title should always be registered with the Editorial Base before the review author starts work.

The preferred format is: [Intervention] in [disorder], and may specify in which population e.g. older people.

Newly registered titles will be publicised throughout the Cochrane Collaboration with the aim of increasing awareness of areas of potential common interest.

### **Protocols are normally expected within 6 months of acceptance of a title.**

If more than one person proposes doing the same review then the UGPD Group will invite both persons to co-operate in the preparation of the review, either by working together, or by independently analysing data and comparing the results. The Co-ordinating Editor will work with the authors to resolve disagreements about authorship of a review.

### **Protocols**

The UGPD Group editorial team supports authors in the preparation of protocols by providing methodological advice, formulation and execution of search strategies, provision of RevMan software and other Cochrane Collaboration materials such as the handbook for authors and training and support as required on an ad hoc basis. Informal advice is available through the Review Group Co-ordinator.

At least three referees are asked to provide comments on each protocol. In general these will be: a person with experience of Cochrane methodology, a clinical expert and a consumer. These referees are usually from outside the editorial team, but editors may be asked to provide referee comments for protocols other than those for which they have editorial responsibility. In the case of methodological difficult or clinically contentious issues, comments may be sought from additional peer referees.

Once comments from referees have been returned to the author, the author is asked to modify the protocol as appropriate and return this to the Review Group Co-ordinator (by submitting it for editorial process through Archie) with a commentary of the changes made and how these address the referees' comments.

Referees will be sent copies of the other referees' comments and the author's response, once the protocol is approved for publication.

Once approved by the contact editor, the editorial team will check and approve the protocol. Final approval for publication will be given by the Co-ordinating Editor. Copy editing will not be done routinely by the UGPD Group at the protocol stage.

The UGPD Group's policy for resolving disagreements between the editorial team and authors or between the authors themselves, about the content of the protocol, is to attempt to resolve such issues by informal discussion. In the event an issue cannot be resolved, the advice of the director of the UK Cochrane Centre will be sought.

**Time between submission of protocol and receipt of the completed review should normally be two years or less.** After this time, protocols will be judged to have 'expired' and will be removed from the Cochrane Library with a note to that effect in the What's New section.

### **Reviews**

The UGPD Group editorial team supports authors in the preparation of reviews by providing methodological advice, formulation and execution of search strategies, provision of RevMan software and other Cochrane Collaboration materials such as the handbook for authors and training and support as required on an ad hoc basis. Informal advice is available through the Review Group Co-ordinator.

At least three referees are asked to provide comments on each review, in general these will be: a person with experience of Cochrane methodology, a clinical expert and a consumer. These referees are usually from outside the editorial team, but editors may be asked to provide referee comments for reviews other than those for which they have editorial responsibility. In the case of methodological difficult or clinically contentious issues, comments may be sought from additional peer referees. Where possible, comments will be sought from the same peer referees who commented on the protocol.

After comments from referees have been returned to the authors, the authors are asked to modify the review as appropriate and return it to the Review Group Co-ordinator with a commentary of the changes made and how these address the referees' comments.

Once approved by an editor, the editorial team will check and approve the review. Final approval for publication will be given by the Co-ordinating Editor. Copy editing will not be done routinely by the UGPD Group but completed reviews are submitted to Wiley's copy editing service and authors will be expected to amend their reviews to reflect these copy edit comments before publication.

The UGPD Group's policy for resolving disagreements between the editorial team and authors or between the authors themselves, about the content of the protocol, is to attempt to resolve such issues by informal discussion. In the event an issue cannot be resolved, the advice of the director of the UK Cochrane Centre will be sought.

Referees will be sent copies of the other referees' comments and the author's response, once the review is approved for publication.

### **Updating**

Review authors will obtain newly identified information which may be relevant to their review from the specialised register on an annual basis.

Reviews will be updated annually when new studies are identified. If no new trials are found at the annual update search, a note will be made on the published review to this effect.

Updates of reviews will not normally be subject to the peer referee process as described for reviews unless the conclusions of the review are substantially altered by the addition of new data.

### **Feedback**

Brendan Delaney is the Feedback Editor appointed by the UGPD, and will oversee the process of dealing with comments and criticisms.

### **Out of date reviews**

Policy to be developed.

### **Disagreements about updates**

The UGPD Group's policy for resolving disagreements between the editorial team and authors or between the authors themselves, about the content of the protocol, is to attempt to resolve such issues by informal discussion. In the event an issue cannot be resolved, the advice of the director of the UK Cochrane Centre will be sought.

### **Plagiarism**

The Group upholds an author's right to intellectual property and will not tolerate plagiarism. Authors are requested to

properly cite or paraphrase another author's work. Copying and pasting the work of others is not acceptable. The Group has procedures in place to detect plagiarism at all stages of review development, including title registration. Authors suspected of plagiarism will be confronted. Depending on the severity of plagiarism an author may be given guidance on how rephrase or quote another's work or, in extreme cases, banned from any further work with the group.

## Publications

### Publications of Cochrane UGPD Reviews

#### Journal Articles/Book Chapters

Arnott S. et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data. *Int. J. Radiation Oncology Biol. Phys.*, 41 (3)579- 583. Also published as: Preoperative radiotherapy for esophageal carcinoma Tierney J. et al. *The Cochrane Library*.

Calvet X., Vergara M, Brullet E, Gisbert JP, Campo R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. *Gastroenterology* 2004; 126: 441-450.

Delaney B. et al. The management of dyspepsia: a systematic review. *Health Technology Assessment* 2000; 4(39). This publication incorporates details of several Cochrane reviews.

Delaney B. Managing dyspepsia and reflux. *The Practitioner* 2003;247:408-411

Delaney BC. et al. Helicobacter pylori infection. *Clinical Evidence* 2001; 5:324-337.

Delaney BC. et al. Helicobacter pylori infection. *Clinical Evidence* 2002; 7: 414-428. (update)

Delaney BC. et al. Helicobacter pylori infection. *Clinical Evidence* 2002; (update in press for issue 8)

Delaney BC, Moayyedi P. Dyspepsia. In: *Health Care Needs Assessment 3rd Series*. Edited by Stevens A, Raftery J, Mant J. Routledge, 2003(in press) also available at: <http://hcna.radcliffe-oxford.com/dysframe.htm>

Delaney BC, O'Morain C. The management of dyspepsia. *The Year in Helicobacter pylori. Current Opinion in Gastroenterology* 2001;17 (1):S38-S42.

Delaney BC. Dyspepsia and Peptic Ulcer Disease. In: *Quality indicators for General Practice*. (eds.) Marshall M, Campbell S, Hacker J, Roland M. Royal Society of Medicine; London, 2001.104-111. [Book chapter]

Delaney BC. Dyspepsia management in the millennium: to test and treat or not? *Gut* 2003; 52:10-11.

Delaney BC. Helicobacter pylori. *Best Treatments 2002* (electronic media): [www.besttreatments.org](http://www.besttreatments.org)

Delaney BC. Making sense of all the dyspepsia Guidelines. *Pulse*. March 24th 2001; 60-68.

Delaney BC. Managing uninvestigated dyspepsia. *Best of DDW CD ROM. Digestive Disease Week 2002*. (electronic media CD ROM).

Delaney BC. Modelling H. pylori 'test and treat' in Primary Care. *European Journal of General Practice* 2001;7:129-131. [Editorial]

Delaney BC. Modern diagnosis and management of dyspepsia. *Member's reference book 2001. Royal College of General Practitioners; London, 2001:63-64.*

Delaney BC. Test and treat for H.pylori. *Gastroimpact: Shire Health; London Autumn 2002: 14-15.*

Delaney B C and Moayyedi P. Eradicating H.pylori does not cause gastro-oesophageal reflux disease. *BMJ* 2004; 328: 1388 - 1389. [Editorial]

Dent J, Armstrong D, Delaney B, Moayyedi P, Talley N J, and Vakil N. Symptom evaluation in reflux disease Proceedings of a workshop held in Marrakech, Morocco Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. *Gut* 2004; 53 (Suppl 4): iv1-iv24.

Ford A, Delaney B. Managing Gastro-oesophageal reflux disease. *Update*. Nov. 2002; 4-6.

Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. *Am J Gastroenterol*. 2004; 99: 1833-55.

Fraser A, Delaney BC, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: A systematic review. *American Journal of Gastroenterology* 2004 (in press)

- Gilbert R. et al. Cisapride for GORD in infants. *Journal of Paediatrics and Child Health*, 2000; 36:524-529. Also published as Cisapride treatment for gastro-oesophageal reflux in children Augood C et al. *The Cochrane Library*.
- JP Gisbert, S Khorrami, F Carballo, X Calvet, E Gene, E Dominguez-Muñoz. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. *Aliment Pharmacol Ther* 2004; 19: 617-629.
- Jankowski J. et al. 10 minute consultation: Gastro-oesophageal reflux disease (GORD). *BMJ* 2002;325:945
- Katzka D. et al. Gastro-oesophageal reflux disease. *Clinical Evidence* 2000; Issue 4:253-265.
- Logan RFA, Delaney BC. Implications of dyspepsia for the NHS. In: *ABC of the Upper Gastrointestinal tract*. (eds) Logan RPH, Harris A, Misiewicz JJ, Baron JH. *BMJ Books*; London, 2002. ISBN 0-7279-1266-6.
- Moayyedi P. et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. *BMJ* 2000, 321:659-664. Also published as Eradication of Helicobacter pylori for non-ulcer dyspepsia Moayyedi P et al. *The Cochrane Library*.
- Moayyedi P. et al. Helicobacter pylori eradication therapy for nonulcer dyspepsia. *Annals of Internal Medicine* 2002; 136: 555-6.
- Moayyedi P. et al. Systematic review: antacids, H2 receptor antagonists, prokinetics, bismuth and sucralfate therapy for non ulcer dyspepsia. *Alimentary Pharm and Ther* 2003;17:1215-1227.
- Moayyedi P. et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. *Aliment Pharmacol Ther* 2003; 17: 1207-14.
- Moayyedi P, Delaney B, Forman D. Gastro-oesophageal reflux disease. *Clinical Evidence* 2003; 9: 89-91.
- Moayyedi P. Helicobacter pylori eradication in non-ulcer dyspepsia: the case for. In: *Helicobacter pylori: Basic mechanisms to clinical cure* 2002. Eds. Hunt RH, Tytgat GNJ. *Kluwer Academic Publishers*, Dordrecht 2002; 265-274.
- Moayyedi P, Delaney BC, Katzka D, Forman D. Gastro-oesophageal reflux disease. *Clinical Evidence* 2000; issue 4: 253-265
- Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. *Am J Gastroenterol* 2003; 98: 2621-6.
- Moayyedi P, Soo S, Deeks J, Forman D, Harris A, Innes M, Delaney B. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. *Alimentary Pharmacology and Therapeutics* 2003; 17: 1207-14.
- Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ, The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. *Gastroenterology* 2004; 127:1329-37.
- Moayyedi P, Duffy J, Delaney B. Symptom evaluation in reflux disease *Proceedings of a workshop held in Marrakech, Morocco New approaches to enhance the accuracy of the diagnosis of reflux disease*. *Gut* 2004; 53 (Suppl 4): iv55-iv57.
- Rostom A. et al. Canadian co-ordination office for health technology assessment. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Due for publication in September 2003
- Rostom A. et al. Prevention of NSAID-induced upper GI toxicity. (manuscript submitted to *Rheumatology*) Also published as Prevention of NSAID-induced gastroduodenal ulcers Rostom A et al. *The Cochrane Library*.
- Rostom, G. et al. The prevention of NSAID Induced Upper Gastrointestinal Toxicity: A meta-Analysis of Randomized controlled Trials. *J of Rheum sept*. 2000; 27(9):2203-14.
- Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. Symptom evaluation in reflux disease *Proceedings of a workshop held in Marrakech, Morocco A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials*. *Gut* 2004; 53 (Suppl 4): iv58-iv65.
- Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. *Am J Gastroenterol*. 2004; 99: 1817-22.
- Soo S. et al. A systematic review of pharmacological therapies in non-ulcer dyspepsia. *Gut* 2000; 46: (suppl 11): A88
- Soo S. A systematic review of pharmacological therapies in non-ulcer dyspepsia. *Digestive Disease Week, San Diego, USA* 2000 (*Gastroenterology* 2000; 118: A440)

Talley NJ, Marshall BJ, Bytzer P, Engstrand L, de Boer W, Vakil N, Delaney B, Jones R, Malfertheiner P, Agréus L. Management Issues in Dyspepsia: Current Consensus and Controversies. *Scandinavian Journal of Gastroenterology* (in press)

Van Binsbergen JJ. et al. Nutrition in Primary Care: scope and relevance of output from the Cochrane Collaboration. *American Journal of Clinical Nutrition*. 2003;77: 1083-1088.

Van Pinxteren B. et al. GERD in primary care. (manuscript in preparation). Also published as Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease van Pinxteren B et al. *The Cochrane Library*.

van Pinxteren B. et al. Short-term Treatment of Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of the Effect of Acid Suppressant Drugs. *J Gen Int Med* 2003, accepted

van Pinxteren B. et al. (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. *Health Technology Assessment Monographs* 5:(24).

#### Abstracts/Oral/Poster Presentations

Delaney B. et al. Effectiveness of prompt endoscopy in the management of dyspepsia: a systematic review. *Digestive Disease Week, Atlanta USA, 20-23 May 2001*.

Delaney B. on behalf of the Dyspepsia Review Group. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of the effectiveness of *Helicobacter pylori* eradication for non-ulcer dyspepsia. 3rd. Symposium on systematic reviews, Oxford July 4-6 2000.

Delaney B. on behalf of the Dyspepsia Review Group. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of the effectiveness of *Helicobacter pylori* eradication for non-ulcer dyspepsia. *European Society for Medical Decision Making ASM, Leiden, Netherlands June 16th. 2000*.

Delaney B. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of the effectiveness of *Helicobacter pylori* eradication for non-ulcer dyspepsia. 9th Cochrane Colloquium, Cape Town, South Africa. October 21-29th 2000.

Delaney B. et al. Cost-Effectiveness of Early Endoscopy for Dyspepsia in Patients of 50 Years of Age and Over: Results of a Primary Care Based Randomised Controlled Trial. *Digestive Disease Week, San Diego USA, 20-24 May 2000*.

Delaney BC, Moayyedi P. Cost-effectiveness of maintenance therapies for oesophagitis: a 2nd order monte carlo simulation based on a meta-analysis. *Society for Medical Decision Making, Chicago, Illinois, USA. October 18-22nd 2003. (Oral)*

Delaney BC, Barton PM, Moayyedi P, Wilson S. A Discrete Event Simulation Of The Cost-Effectiveness Of Detecting Upper Gi Cancer By Prompt Endoscopy In Dyspeptic Patients Above Different Ages. *Society for Medical Decision Making, Chicago, Illinois, USA. October 18-22nd 2003. (Poster)*

Delaney BC, Qume M, Ford A, O'Rourke K, Moayyedi P, The management of dyspepsia in primary care: a prospective individual patient data meta-analysis of health economic RCTs. *Cochrane Colloquium, Barcelona, Spain 25th-31st October 2003. (poster)*

Delaney BC, Moayyedi P, Mason M. Using Cochrane Reviews And Modelling In The Development Of UK National Guidelines On Dyspepsia. *Cochrane Colloquium, Barcelona, Spain 25th-31st October 2003. (Oral)*

Delaney BC, Qume M, Ford A, Moayyedi P, on behalf of the Dyspepsia Trials Collaborators' Group. The management of dyspepsia in primary care: a prospective individual patient data meta-analysis of health economic RCTs. *European Society For Medical Decision Making, Rotterdam June 2004 (Poster)*

Delaney BC, Moayyedi P, Mason M. Using Cochrane Reviews And Modelling In The Development Of UK National Guidelines On Dyspepsia. *European Society For Medical Decision Making, Rotterdam June 2004 (Poster)*

Delaney BC, Ford A, Qume M, Moayyedi P, . Test and treat v. prompt endoscopy: an individual patient data meta-analysis. *North American Primary Care Research Group, Orlando, USA 12th Oct 2004. (Oral)*

Delaney BC, Ford A, Qume M, Moayyedi P. Test and treat v. prompt endoscopy: an individual patient data meta-analysis. *Society for Medical Decision Making, Atlanta, USA 19th Oct 2004. (Poster)*

Ford A, Qume M, Moayyedi P, Delaney BC. Test and treat v. prompt endoscopy: an individual patient data meta-analysis. *Digestive Disease Week New Orleans, USA 19th May 2004. (Oral)*

Gisbert, J. H. *pylori* (HP) Eradication Therapy vs. Antisecretory Non-Eradication Therapy for the Prevention of Recurrent Bleeding (RB) from Peptic Ulcer (PU): a Cochrane Systematic (*Helicobacter* 2004; 9: 567)

Gisbert J.P., Khorrani S., Carballo F., Calvet X., Gene E., Dominguez-Muñoz E., Pajares J.M., H. pylori (HP) Eradication Therapy vs. Antisecretory Non-Eradication Therapy for the Prevention of Recurrent Bleeding (RB) from Peptic Ulcer (PU): a Cochrane Systematic Review.. *Gastroenterology* 2004; 126 (Suppl.2): T1185. Presented in the last European Helicobacter Study Group Congress in Vienna has been awarded as "Poster of Distinction".

Innes M.A. et al. Managing dyspepsia in primary care: a systematic review. Association of University Departments of General Practice, Annual Scientific Meeting, London 1999.

Innes M.A. et al, Managing dyspepsia in Primary Care: A systematic review. *Gastroenterology* 2000; 118 Suppl 2: A1249.

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Cochrane collaboration systematic review and meta-analysis of proton pump inhibitor treatment for peptic ulcer bleeding. *Gut* 2003; 52 (Suppl IV): A18 11th United European Gastroenterology Week, Madrid, 1-5 November 2003.

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Influence of geographical location of randomized controlled trials on effectiveness of PPI treatment in ulcer bleeding: A post hoc analysis of a Cochrane Collaboration systematic review. *Gastroenterology* 2004, 126: A-192 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Efficacy of PPI treatment for ulcer bleeding when compared with placebo or an H2-receptor antagonist: A sub-group analysis from the Cochrane Collaboration systematic review. *Gastroenterology* 2004; 126: A-193 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Does the efficacy of PPI treatment for ulcer bleeding depend on the nature of pre-randomization endoscopic stigmata? A post hoc analysis from the Cochrane Collaboration systematic review. *Gastroenterology* 2004; 126: A-603 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. The influence of PPI dose on treatment efficacy for ulcer bleeding following endoscopic emostatic therapy: A sub-group analysis from the Cochrane Collaboration systematic review. *Gastroenterology* 2004; 126: A-602 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Moayyedi P. A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD) British Society of Gastroenterology, Birmingham, UK 2000 (*Gut* 2000; 46 (suppl 11): A51

Moayyedi P. et al. A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD). *Gastroenterology* 2000; 118: A471

Moayyedi P. et al. Markov modelling with probabilistic sensitivity analysis based on meta-analysis: cost-effectiveness of Helicobacter pylori eradication for non-ulcer dyspepsia. Society for Medical Decision Making, 22nd Annual Scientific Meeting, Cincinnati, USA. September 24-27th 2000. (Poster presentation)

van Pinxteren B. et al. Short-term Treatment with Proton Pump inhibitors, H2-receptor antagonists and Prokinetics in Gastroesophageal Reflux Disease: A systematic review. Poster Presentation at DDW 2000, San Diego CA, USA, May 22 2000 (abstract published in *Gastroenterology*).

Wong, K.S.R. Is combination radiotherapy chemotherapy (RTCT) superior to radiotherapy (RT) alone in the non-surgical management of localized esophageal carcinoma? A systematic review. (abstr) *Suppl Clin Inv Med* 372 S50 1999. Royal College of Physicians and Surgeons of Canada. Montreal, Quebec. September 1999.

Wong K.S.R. Meta-analysis of Combined Chemotherapy and Radiotherapy for Esophageal Cancer. ASTRO, American Society of Therapeutic Radiation Oncology. San Antonio, TX. September 1999.

#### Plenaries and Workshops

Briggs A, Delaney BC; Schulpher M, Claxton K. Stochastic cost-effectiveness modelling. Society for Medical Decision Making. Chicago, Illinois, USA. October 21st 2003. (invited postgraduate course)

Delaney B.C. The role of quality of life measurement in the clinical assessment of GERD. Symptom assessment in reflux disease. Marrakech, Morocco, 7-8th September 2002.

Delaney B.C. Test and treat strategies for H.pylori in the management of dyspepsia. Chris Silagy memorial lecture: The impact of systematic reviews on primary care. Kellogg College, Oxford. 26th Sept 2002.

Delaney B.C. 'Pragmatic' RCTs : planning, conduct and analysis of RCTs with cost-effectiveness as the primary outcome. Epidemiology Grand Round, McGill University Health Centre, Montreal Canada, October 8th 2002.

Delaney B.C. A Bayesian approach to dyspepsia: working with uncertainty at the interface between research and practice. Invited lecture, Montreal, Canada 8th October 2002.

Delaney B.C. The Cochrane Collaboration and the evidence-base for managing dyspepsia. Gastroenterology Grand Round, Montreal General Hospital, Montreal, Canada. 9th October 2002.

Delaney B. Effectiveness of empirical treatments for undiagnosed dyspepsia. Primary Care Society for Gastroenterology Symposium at The British Society of Gastroenterology ASM, Birmingham, March 21-23, 2000.

Delaney B. Evidence-based management of dyspepsia. Primary Care Society for Gastroenterology ASM, Birmingham, October 13th 2000.

Delaney B. Vale L. Exploring uncertainty in economic analysis: ways of extending systematic reviews to address issues of cost-effectiveness. 9th Cochrane Colloquium, Cape Town, South Africa. October 21-29th 2000. (Invited Workshop)

Delaney BC. Managing dyspepsia in primary care. XVIth International Workshop Gastrointestinal Pathology and Helicobacter. Stockholm 4-6 September 2003.

Delaney BC. Prevalence and epidemiology of GERD. Europe-Japan Joint Expert meeting, London, 22nd Sept 2003.

Delaney BC. Managing dyspepsia in Primary Care A new Cochrane individual patient data meta-analysis. (AGA Special Symposium) Digestive Disease week, New Orleans, USA 19th May 2004.

Delaney BC. Management of Dyspepsia. (invited talk) WONCA-Europe, Amsterdam 3 June 2004.

Delaney BC. Dyspepsia management: H pylori and beyond (invited talk). United European Gastroenterology week, Prague 27th Sept 2004.

Delaney BC. Approach to the patient with dyspepsia (lunch session). United European Gastroenterology week, Prague 28th Sept 2004.

Delaney BC. Dyspepsia: Test and treat. Takeda Satellite symposium:United European Gastroenterology week, Prague 28th Sept 2004

Delaney BC. Acute management of the patient with Gastroesophageal reflux disease: Workshop on Gastrointestinal Disease, Paris 21st Oct 2004

Incorporation of reviews into guidelines/discussion of reviews at meetings (e.g. consensus conferences)

NHS Executive Evidence Review: "Improving Outcomes in Upper GI Cancers". This evidence review has been published and used by the NHS Centre for Research and Development in the development of their manual: "Guidance on Commissioning Cancer Services: Upper GI Cancer". The Manual will, in turn, be used by Health Authorities to provide guidance in the commissioning of relevant services.

The review "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease" will be included in primary care guidelines by the European Society for Primary Care Gastroenterology.

The HTA Report: "Managing the Dyspeptic Patient" will be used as the evidence base for the production of guidelines by the British Society of Gastroenterology.

Dr R. Malthaner (UGPD editor and reviewer) and Dr Wong (UGPD reviewer) are contributing reviews of chemo- or radiotherapy as adjuvant or neoadjuvant therapy for oesophageal resectable cancer and took the lead in drafting and revising the Cancer Care Ontario Practice Guidelines Initiative, recently submitted to "Cancer Practice and Control".

Tierney, J The results of the pre-op RT in oesophageal cancer are included in the British Columbia Cancer Agency Cancer Management Guidelines for Gastrointestinal Cancer.

<http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gastrointestinal/01.EsophagusAndCardia/Management/Localiz>

## References

## Additional information